COIL logo

Coiled Therapeutics plcAIM:COIL Stock Report

Market Cap UK£35.1m
Share Price
UK£0.071
My Fair Value
n/a
1Y-61.5%
7D-13.6%
Portfolio Value
​
View

Coiled Therapeutics plc

AIM:COIL Stock Report

Market Cap: UK£35.1m

Coiled Therapeutics (COIL) Stock Overview

A clinical stage oncology company, develops precision oncology therapies. More details

COIL fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health0/6
Dividends0/6

Risk Analysis

Has not reported any financial data

Does not have a meaningful market cap (£35M)

Volatile share price over the past 3 months compared to the UK market


COIL Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

View all narratives
GANX logo
GANXFeatured

The Market Is Sleeping on This Parkinson's Biotech - And I Think That's a Mistake

Gain Therapeutics: The Under-the-Radar Biotech With Big Parkinson’s Potential Key Takeaways Gain Therapeutics (GANX) is developing GT-02287 – an oral, first-in-class, potentially disease-modifying treatment for Parkinson’s disease targeting the GCase enzyme pathway. Parkinson’s disease represents a $4 billion U.S. market with zero approved disease-modifying therapies.
View narrative
Community Contributor
US$7.6FV • 72.5% undervalued intrinsic discount
5022.2%Revenue growth p.a.
3.3k
21
2
46
19d ago

Coiled Therapeutics plc Competitors

Price History & Performance

Summary of share price highs, lows and changes for Coiled Therapeutics
Historical stock prices
Current Share PriceUK£0.071
52 Week HighUK£0.30
52 Week LowUK£0.068
Beta0
1 Month Change-30.49%
3 Month Change-47.22%
1 Year Change-61.49%
3 Year Change-89.44%
5 Year Change-91.62%
Change since IPO-89.44%

Recent News & Updates

Recent updates

Shareholder Returns

COILGB BiotechsGB Market
7D-13.6%-2.1%-0.7%
1Y-61.5%37.8%26.1%

Return vs Industry: COIL underperformed the UK Biotechs industry which returned 37.8% over the past year.

Return vs Market: COIL underperformed the UK Market which returned 26.1% over the past year.

Price Volatility

Is COIL's price volatile compared to industry and market?
COIL volatility
COIL Average Weekly Movement11.2%
Biotechs Industry Average Movement8.2%
Market Average Movement5.7%
10% most volatile stocks in GB Market11.9%
10% least volatile stocks in GB Market3.2%

Stable Share Price: COIL's share price has been volatile over the past 3 months compared to the UK market.

Volatility Over Time: COIL's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of UK stocks.

About the Company

FoundedEmployeesCEOWebsite
n/an/aSridhar Vempaticoiledplc.com

Coiled Therapeutics plc, a clinical stage oncology company, develops precision oncology therapies. It develops AO-252, a TACC3 inhibitor that is in Phase I clinical trials; and STAT-6 siRNA program, which is in preclinical trials for treating immunology indications. The company is based in London, United Kingdom.

Coiled Therapeutics plc Fundamentals Summary

How do Coiled Therapeutics's earnings and revenue compare to its market cap?
COIL fundamental statistics
Market capUK£35.13m
Earnings (TTM)UK£0
Revenue (TTM)n/a
n/a
P/E Ratio
n/a
P/S Ratio

Is COIL overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
COIL income statement (TTM)
RevenueUK£0
Cost of RevenueUK£0
Gross ProfitUK£0
Other ExpensesUK£0
EarningsUK£0

Last Reported Earnings

n/a

Next Earnings Date

n/a

Earnings per share (EPS)0
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0.0%

How did COIL perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/04/22 20:03
End of Day Share Price 2026/04/22 00:00
EarningsN/A
Annual EarningsN/A

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Coiled Therapeutics plc is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.